Alnylam Pharmaceuticals, a biopharmaceutical company headquartered in Cambridge, Mass, has named Michael Bonney as Chairman to replace John Clarke who stepped down after 13 years of service. Clarke will remain on the board as a director of the company. Bonny is the current board member and former CEO of Cubist Pharmaceuticals.
“We welcome Bonney to his newly appointed role leading the board through our transition toward a commercial stage company. He led the transition of Cubist from a research and development company to a successful commercial enterprise, and we welcome the leadership he’ll bring to our Board,” said John Maraganore, CEO at Alnylam.
Bonney served as CEO of Cubist from June 2003 until his retirement in December 2014. From January 2002 to June 2003, he worked as Cubist’s President and COO, and from 1995 to 2001, he held various positions at Biogen.
Meanwhile, David Pyott was added to the board at Alnylam. He acted as CEO of Allergan from 1998 to 2015. Prior to Allergan, Pyott was the Head of the Novartis Nutrition Division and a member of the Executive Committee of Switzerland-based Novartis AG. “Pyott’s commercial expertise and experience in organisational scaling will be invaluable to Alnylam as we become a commercial biopharmaceutical company,” noted Maraganore.
Alnylam’s board of directors include Bonney, Dennis Ausiello, Clarke, Marsha H. Fanucci, Maraganore, Steven M. Paul, Pyott, Paul Schimmel, Amy Schulman, Phillip Sharp and Kevin Starr.
In December 2014, Alnylam established an evolution in its strategy with a focus on development and commercialization of investigational RNAi therapeutics in genetic medicine, cardio-metabolic and hepatic infectious disease. In January 2015, the firm launched its “Alnylam 2020” guidance that reflects its expected transition from a late-stage clinical development company to a multi-product commercial-stage company with a sustainable development pipeline.